AstraZeneca Bid to Block Medicare Price Talks Barred, HHS Says

AstraZeneca’s effort to block Medicare negotiations over prescription drug prices can’t be heard before a federal court because the company lacks standing and because the law that created the program “explicitly barred” its claims, the Biden administration said.

"[N]ow that their lobbying has failed, pharmaceutical companies and interest groups have repackaged their policy disagreements into lawsuits, filing complaints around the country challenging the Negotiation Program on a variety of grounds,” President Joe Biden’s Department of Health and Human Services said in its filing.

AstraZeneca PLC‘s case is among those suits, but “fares no better than the others,” the ...